235 related articles for article (PubMed ID: 7532163)
1. Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma.
Rodriguez G
Invest New Drugs; 1994; 12(2):75-92. PubMed ID: 7532163
[TBL] [Abstract][Full Text] [Related]
2. Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies.
Chun HG; Leyland-Jones B; Cheson BD
J Clin Oncol; 1991 Jan; 9(1):175-88. PubMed ID: 1702143
[TBL] [Abstract][Full Text] [Related]
3. Fludarabine phosphate therapy in other lymphoid malignancies.
Kantarjian HM; Redman JR; Keating MJ
Semin Oncol; 1990 Oct; 17(5 Suppl 8):66-70. PubMed ID: 1699285
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive phase I and II clinical investigation of fludarabine phosphate.
Grever M; Leiby J; Kraut E; Metz E; Neidhart J; Balcerzak S; Malspeis L
Semin Oncol; 1990 Oct; 17(5 Suppl 8):39-48. PubMed ID: 1699282
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia.
Rossi JF; van Hoof A; de Boeck K; Johnson SA; Bron D; Foussard C; Lister TA; Berthou C; Kramer MH; Littlewood TJ; Marcus RE; Deconinck E; Montillo M; Guibon O; Tollerfield SM
J Clin Oncol; 2004 Apr; 22(7):1260-7. PubMed ID: 15051774
[TBL] [Abstract][Full Text] [Related]
6. [Phase I clinical study of SH L573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia and adult T-cell leukemia/lymphoma].
Arima N; Mizoguchi H; Shirakawa S; Tomonaga M; Takatsuki K; Ohno R
Gan To Kagaku Ryoho; 1999 Apr; 26(5):619-29. PubMed ID: 10234292
[TBL] [Abstract][Full Text] [Related]
7. Fludarabine phosphate in lymphoma: an important new therapeutic agent.
McLaughlin P; Robertson LE; Keating MJ
Cancer Treat Res; 1996; 85():3-14. PubMed ID: 9043771
[No Abstract] [Full Text] [Related]
8. Phase I clinical trials with fludarabine phosphate.
Von Hoff DD
Semin Oncol; 1990 Oct; 17(5 Suppl 8):33-8. PubMed ID: 1699281
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine phosphate: an effective therapy for lymphoid malignancies.
Semin Oncol; 1990 Oct; 17(5 Suppl 8):1-78. PubMed ID: 1699278
[No Abstract] [Full Text] [Related]
10. Treatment of advanced chronic lymphocytic leukemia by fludarabine. Results of a clinical phase-II study.
Hiddemann W; Rottmann R; Wörmann B; Thiel A; Essink M; Ottensmeier C; Freund M; Büchner T; van de Loo J
Ann Hematol; 1991 Jul; 63(1):1-4. PubMed ID: 1715191
[TBL] [Abstract][Full Text] [Related]
11. New initiatives with fludarabine monophosphate in hematologic malignancies.
Keating MJ; O'Brien S; Robertson LE; Kantarjian H; Dimopoulos M; McLaughlin P; Cabanillas F; Gregoire V; Yang LY; Gandhi V
Semin Oncol; 1993 Oct; 20(5 Suppl 7):13-20. PubMed ID: 7694371
[TBL] [Abstract][Full Text] [Related]
12. In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
Kano Y; Akutsu M; Tsunoda S; Suzuki K; Ichikawa A; Furukawa Y; Bai L; Kon K
Leukemia; 2000 Mar; 14(3):379-88. PubMed ID: 10720130
[TBL] [Abstract][Full Text] [Related]
13. Fludarabine phosphate: a new active agent in hematologic malignancies.
Keating MJ; O'Brien S; Plunkett W; Robertson LE; Gandhi V; Estey E; Dimopoulos M; Cabanillas F; Kemena A; Kantarjian H
Semin Hematol; 1994 Jan; 31(1):28-39. PubMed ID: 7510070
[No Abstract] [Full Text] [Related]
14. Fludarabine phosphate in the treatment of chronic lymphocytic leukemia: biology, clinical impact, and future directions.
Robertson LE; Keating MJ
Cancer Treat Res; 1993; 64():105-19. PubMed ID: 7680874
[No Abstract] [Full Text] [Related]
15. [The use of fludarabine phosphate (Fludara) to treat chronic B-cell lymphocytic leukemia and non-Hodgkin's lymphoma resistant to standard chemotherapy].
Gershanovich ML; Zaritskiĭ AIu; Medvedeva NV; Abdulkadyrov KM; Samuskevich IG; Beresneva IA
Vopr Onkol; 1998; 44(6):696-700. PubMed ID: 10087967
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia.
Grever MR; Kopecky KJ; Coltman CA; Files JC; Greenberg BR; Hutton JJ; Talley R; Von Hoff DD; Balcerzak SP
Nouv Rev Fr Hematol (1978); 1988; 30(5-6):457-9. PubMed ID: 2464793
[TBL] [Abstract][Full Text] [Related]
17. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma.
Foran JM; Rohatiner AZ; Coiffier B; Barbui T; Johnson SA; Hiddemann W; Radford JA; Norton AJ; Tollerfield SM; Wilson MP; Lister TA
J Clin Oncol; 1999 Feb; 17(2):546-53. PubMed ID: 10080598
[TBL] [Abstract][Full Text] [Related]
18. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia.
Boogaerts MA; Van Hoof A; Catovsky D; Kovacs M; Montillo M; Zinzani PL; Binet JL; Feremans W; Marcus R; Bosch F; Verhoef G; Klein M
J Clin Oncol; 2001 Nov; 19(22):4252-8. PubMed ID: 11709569
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine in chronic leukaemia.
Astrow AB
Lancet; 1996 May; 347(9013):1420-1. PubMed ID: 8676619
[No Abstract] [Full Text] [Related]
20. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report.
Sorensen JM; Vena DA; Fallavollita A; Chun HG; Cheson BD
J Clin Oncol; 1997 Feb; 15(2):458-65. PubMed ID: 9053466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
